Hypercoagulation after neoadjuvant immunochemotherapy as a new prognostic indicator in patients with locally advanced gastric cancer undergoing surgery

doi:10.4251/wjgo.v17.i3.100927

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (191)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-4)

Tables (1-3)

Sum=161

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=21

Mar 15, 2025 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Mar 15, 2025; 17(3): 100927
Published online Mar 15, 2025. doi: 10.4251/wjgo.v17.i3.100927

Hypercoagulation after neoadjuvant immunochemotherapy as a new prognostic indicator in patients with locally advanced gastric cancer undergoing surgery

Tian-Hao Li, Xiong Sun, Cheng-Guo Li, Yu-Ping Yin, Kai-Xiong Tao

Tian-Hao Li, Xiong Sun, Cheng-Guo Li, Yu-Ping Yin, Kai-Xiong Tao, Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China

Co-first authors: Tian-Hao Li and Xiong Sun.

Co-corresponding authors: Yu-Ping Yin and Kai-Xiong Tao.

Author contributions: Yin YP and Tao KX had full access to all the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis; Li TH, Sun X and Li CG participated in the acquisition, analysis, and interpretation of data; Li TH drafted the manuscript. All authors critically reviewed and provided final approval of the manuscript; all authors were responsible for the decision to submit the manuscript for publication. Li TH, Sun X and Yin YP contributed to the concept and design of this study. Here is the rationale for designating two as co-corresponding authors. This manuscript has been assigned two co-corresponding authors in recognition of their equally vital contributions to the research. Dr. Yin YP provided strategic direction and data support, while Dr. Tao KX secured the necessary funding and led the research initiative. Both researchers were equally involved in every aspect of the study, from conceptualization to implementation. It is only fitting to acknowledge their joint efforts by naming them as co-corresponding authors. Together, they are also entrusted with ensuring the precision and completeness of the research, which facilitates more effective oversight and management of the publication process. Consequently, we have chosen to list them as co-corresponding authors.

Supported by Natural Science Foundation of Hubei Province of China, No. 2024AFB655; Key Research and Development Program of Hubei Province of China, No. 2021BCA116; and National Natural Science Foundation of China, No. 82072736, No. 82003205, No. 82373123 and No. 82473175.

Institutional review board statement: This investigation was approved by the Institutional Ethics Committee of Wuhan Union Hospital, No. 2020-0447.

Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

Conflict-of-interest statement: The authors have no potential conflicts of interest to declare.

Data sharing statement: No additional data are available.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Yu-Ping Yin, MD, PhD, Doctor, Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan 430022, Hubei Province, China. yinyuping2017@hust.edu.cn

Received: August 30, 2024
Revised: December 6, 2024
Accepted: December 25, 2024
Published online: March 15, 2025
Processing time: 167 Days and 23.2 Hours

Core Tip

Core Tip: This retrospective study assessed the correlation between hypercoagulation after neoadjuvant immunochemotherapy (NICT) and the prognosis of patients with locally advanced gastric cancer (LAGC). Results indicated that the non-hypercoagulation group exhibited significantly superior overall survival (OS) and disease-free survival (DFS) rates compared with the hypercoagulation group. Furthermore, multivariate analysis revealed that hypercoagulation after NICT was an independent risk factor for adverse postoperative OS and DFS. This suggests that hypercoagulation after NICT is an independent prognostic indicator of LAGC and may be used to evaluate therapeutic effects.